Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Jolly, Elaine C., Clatworthy, Menna R., Lawrence, Christopher, Nathan, Paul D., Farrington, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421243/
https://www.ncbi.nlm.nih.gov/pubmed/25984021
http://dx.doi.org/10.1093/ndtplus/sfp048
_version_ 1782369824573227008
author Jolly, Elaine C.
Clatworthy, Menna R.
Lawrence, Christopher
Nathan, Paul D.
Farrington, Ken
author_facet Jolly, Elaine C.
Clatworthy, Menna R.
Lawrence, Christopher
Nathan, Paul D.
Farrington, Ken
author_sort Jolly, Elaine C.
collection PubMed
description Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.
format Online
Article
Text
id pubmed-4421243
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44212432015-05-15 Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis Jolly, Elaine C. Clatworthy, Menna R. Lawrence, Christopher Nathan, Paul D. Farrington, Ken NDT Plus Case Report Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy. Oxford University Press 2009-08 2009-04-28 /pmc/articles/PMC4421243/ /pubmed/25984021 http://dx.doi.org/10.1093/ndtplus/sfp048 Text en © The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Jolly, Elaine C.
Clatworthy, Menna R.
Lawrence, Christopher
Nathan, Paul D.
Farrington, Ken
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title_full Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title_fullStr Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title_full_unstemmed Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title_short Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
title_sort anti-ctla-4 (cd 152) monoclonal antibody-induced autoimmune interstitial nephritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421243/
https://www.ncbi.nlm.nih.gov/pubmed/25984021
http://dx.doi.org/10.1093/ndtplus/sfp048
work_keys_str_mv AT jollyelainec antictla4cd152monoclonalantibodyinducedautoimmuneinterstitialnephritis
AT clatworthymennar antictla4cd152monoclonalantibodyinducedautoimmuneinterstitialnephritis
AT lawrencechristopher antictla4cd152monoclonalantibodyinducedautoimmuneinterstitialnephritis
AT nathanpauld antictla4cd152monoclonalantibodyinducedautoimmuneinterstitialnephritis
AT farringtonken antictla4cd152monoclonalantibodyinducedautoimmuneinterstitialnephritis

Ejemplares similares